Trial reportAmerican journal of respiratory and critical care medicine2022
Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial.
Open access · greenAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph
Trial report in American journal of respiratory and critical care medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 30 citations in OpenAlex.
- A Phase 2a Study of the Early Bactericidal Activity of Rifampicin in Combination With Meropenem Plus Amoxicillin/Clavulanate Among Adults With Rifampicin-Resistant Pulmonary Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Genetic interference of distinctive Mycobacterium tuberculosis peptidoglycan modifications enhances β-lactam susceptibility and reveals expression-sensitive host immune dynamics.Scientific reports · 2026Article
- Therapeutic drug monitoring-guided treatment of XDR TB with an RpoB I491F mutation-a case report.JAC-antimicrobial resistance · 2026Article
- Current and emerging therapies for pulmonary tuberculosis in adults.BMJ medicine · 2026Review
- Recent advancements in drug development for pulmonary tuberculosis.Archives of microbiology · 2025Review
- Prospects of Inhalable Formulations of Conventionally Administered Repurposed Drugs for Adjunctive Treatment of Drug-Resistant Tuberculosis: Supporting Evidence from Clinical Trials and Cohort Studies.Journal of aerosol medicine and pulmonary drug delivery · 2025Review
- Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2025Article
- Clinical Pharmacokinetics of Antitubercular Drugs in the Overweight and Obese Population: Implications for Dosage Adjustments.Clinical pharmacokinetics · 2025Review
- Advances and prospects for treatment strategies of drug-resistant tuberculosis: a review.GMS hygiene and infection control · 2025Review
- Toward better cures forClinical microbiology reviews · 2024Review
- Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis.bioRxiv : the preprint server for biology · 2024Article
- ISCCM Position Statement on the Approach to and Management of Critically Ill Patients with Tuberculosis.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024Article
- A pairwise approach to revitalize β-lactams for the treatment of TB.Antimicrobial agents and chemotherapy · 2024Article
- Power to identify exposure-response relationships in phase IIa pulmonary tuberculosis trials with multi-dimensional bacterial load modeling.CPT: pharmacometrics & systems pharmacology · 2024Article
- The fall of the mycobacterial cell wall: interrogating peptidoglycan synthesis for novel anti-TB agents.PeerJ · 2024Review
- Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen.International journal of antimicrobial agents · 2023Article
- Article
- Mutations inmBio · 2023Article
- Repurposing β-Lactams for the Treatment ofAntibiotics (Basel, Switzerland) · 2023Article
- Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development.Frontiers in pharmacology · 2023Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 5 institutions in 5 countries.
Veronique De JagerTASK Applied Science, Cape Town, South Africa.ORCID 0000-0001-6389-5575
Nikhil GupteDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Silvia NunesTASK Applied Science, Cape Town, South Africa.
Grace L BarnesDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Rob Christiaan van WijkDepartment of Pharmaceutical Biosciences and.ORCID 0000-0001-7247-1360
Joni MostertTASK Applied Science, Cape Town, South Africa.
Susan E DormanMedical University of South Carolina, Charleston, South Carolina.
Ahmed A AbulfathiDepartment of Medicine, Stellenbosch University, Cape Town, South Africa.
Caryn M UptonTASK Applied Science, Cape Town, South Africa.
Alan FarajDepartment of Pharmaceutical Biosciences and.
Eric L NuermbergerDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Gyanu LamichhaneDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Elin M SvenssonDepartment of Pharmacy, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-0093-6445
Ulrika S H SimonssonDepartment of Pharmaceutical Biosciences and.ORCID 0000-0002-3424-9686
Andreas H DiaconTASK Applied Science, Cape Town, South Africa.
Kelly E DooleyDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0001-9013-5256
Johns Hopkins University · USTask Applied Science · ZAMedical University of South Carolina · USStellenbosch University · ZAUppsala University · SE
Funding
Ph2a Study: Rifampin, Merrem, Augmentin for Tuberculosis IND 129159; 12/31/2015R01FD005724 · FDA · JOHNS HOPKINS UNIVERSITY · PI DOOLEY, KELLY E. · 2017 to 2020
$2.0MMentoring Investigators in HIV and Tuberculosis Therapeutics ResearchK24AI150349 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DOOLEY, KELLY E. · 2020 to 2025
$789kFDA HHS R01 FD005724National Institute of Allergy and Infectious Diseases K24AI150349NIAID NIH HHS K24 AI150349U.S. Food and Drug Administration R01FD005724
Abstract
PubMed holds no abstract for this paper.
Indexed as
RifampinTuberculosis, PulmonaryAmoxicillinAntitubercular AgentsClavulanic AcidDrug Therapy, CombinationHumansIsoniazidMeropenemAmoxicillinAntitubercular AgentsClavulanic AcidIsoniazidMeropenemRifampincarbapenemearly bactericidal activitymeropenemphase 2A clinical trialtuberculosis
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.